Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVCOTCMKTS:CBSCNASDAQ:PASGNASDAQ:ZCMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVCABVC BioPharma$1.77-4.3%$1.23$0.40▼$1.85$30.06M0.19306,871 shs284,833 shsCBSCCB Scientific$0.04$0.04$0.02▼$0.15$7.22M1.2262,527 shsN/APASGPassage Bio$0.39-9.1%$0.37$0.26▼$1.33$24.30M1.71362,181 shs117,953 shsZCMDZhongchao$1.15-12.9%$1.19$0.95▼$2.97$29.00M-0.03353,339 shs1.32 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVCABVC BioPharma-4.32%+14.94%+21.23%+174.04%+106.37%CBSCCB Scientific-0.05%+9.38%+19.14%+10.20%-41.23%PASGPassage Bio-9.43%-7.52%+46.66%+1.30%-62.04%ZCMDZhongchao-12.88%+12.09%0.00%-13.53%-3.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABVCABVC BioPharma0.5849 of 5 stars0.03.00.00.03.30.80.0CBSCCB ScientificN/AN/AN/AN/AN/AN/AN/AN/APASGPassage Bio2.7597 of 5 stars3.52.00.00.02.71.71.3ZCMDZhongchao0.8902 of 5 stars0.03.00.00.02.51.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVCABVC BioPharma 0.00N/AN/AN/ACBSCCB Scientific 0.00N/AN/AN/APASGPassage Bio 3.00Buy$7.501,818.16% UpsideZCMDZhongchao 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVCABVC BioPharma$508.38K59.12N/AN/A$1.02 per share1.74CBSCCB Scientific$140K51.53N/AN/AN/A∞PASGPassage BioN/AN/AN/AN/A$2.03 per shareN/AZCMDZhongchao$15.86M1.83N/AN/A$10.24 per share0.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVCABVC BioPharma-$10.52M-$0.13N/A∞N/A-1,619.65%-104.94%-56.81%8/12/2025 (Estimated)CBSCCB ScientificN/AN/A0.00∞N/AN/AN/AN/AN/APASGPassage Bio-$102.06M-$1.02N/AN/AN/AN/A-72.53%-52.10%8/6/2025 (Estimated)ZCMDZhongchao-$11.34MN/A0.00∞N/AN/AN/AN/AN/ALatest CBSC, PASG, ABVC, and ZCMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025PASGPassage Bio-$0.24-$0.25-$0.01-$0.25N/AN/A4/30/2025Q4 2024ABVCABVC BioPharmaN/A-$0.06N/A-$0.06N/AN/A4/15/2025Q4 2024ABVCABVC BioPharmaN/A$0.04N/A$0.04N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABVCABVC BioPharmaN/AN/AN/AN/AN/ACBSCCB ScientificN/AN/AN/AN/AN/APASGPassage BioN/AN/AN/AN/AN/AZCMDZhongchaoN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVCABVC BioPharmaN/A0.340.34CBSCCB ScientificN/AN/AN/APASGPassage BioN/A5.155.15ZCMDZhongchaoN/A6.055.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVCABVC BioPharma11.38%CBSCCB ScientificN/APASGPassage Bio53.48%ZCMDZhongchao1.67%Insider OwnershipCompanyInsider OwnershipABVCABVC BioPharma17.10%CBSCCB ScientificN/APASGPassage Bio5.00%ZCMDZhongchao28.63%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVCABVC BioPharma3016.98 million11.43 millionNot OptionableCBSCCB Scientific5163.67 millionN/ANot OptionablePASGPassage Bio13062.15 million59.11 millionOptionableZCMDZhongchao14025.22 million18.00 millionNot OptionableCBSC, PASG, ABVC, and ZCMD HeadlinesRecent News About These CompaniesWe're Keeping An Eye On Zhongchao's (NASDAQ:ZCMD) Cash Burn RateApril 27, 2025 | finance.yahoo.comZhongchao Inc. Expands Equity Base Through Private Placement and Warrant ExerciseDecember 13, 2024 | tipranks.comZhongchao Inc. Reports Mixed Financial Results for 2024November 2, 2024 | markets.businessinsider.comWhat's Going On With Zhongchao Stock Today?September 30, 2024 | msn.comWhy Is Scorpius (SCPX) Stock Down 79% Today?August 7, 2024 | msn.comWhy Is Zhongchao (ZCMD) Stock Up 52% Today?August 7, 2024 | investorplace.comZhongchao Inc. (ZCMD)July 19, 2024 | finance.yahoo.comZhongchao Full Year 2023 Earnings: US$4.35 loss per share (vs US$1.13 loss in FY 2022)May 3, 2024 | finance.yahoo.comWhy Is Zhongchao (ZCMD) Stock Up 103% Today?April 19, 2024 | investorplace.comZHONGCHAO Inc Ordinary Shares - Class AApril 16, 2024 | morningstar.comAltice USA, Genfit, Brooge Energy among premarket losers' packApril 5, 2024 | msn.comWhy Is Zhongchao (ZCMD) Stock Up 40% Today?April 4, 2024 | investorplace.comZhongchao Inc. Announces Successful Medication Assistance Services for Over 7,000 SLE Patients with Approximately 130,000 Units of MedicationsMarch 12, 2024 | prnewswire.comWhy Paymentus Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving PremarketMarch 5, 2024 | msn.comWhy Is Zhongchao (ZCMD) Stock Up 15% Today?March 5, 2024 | investorplace.comZhongchao Inc. Announces 1-for-10 Share ConsolidationFebruary 27, 2024 | prnewswire.comZhongchao First Half 2023 Earnings: US$0.18 loss per share (vs US$0.004 profit in 1H 2022)December 28, 2023 | finance.yahoo.comZhongchao Inc. Collaborates with a Public Health Foundation to Support Sustainable and Effective Cancer TreatmentsDecember 11, 2023 | finance.yahoo.comZhongchao Inc. Launches Breast Cancer Follow-up Visit and Health Management Patient Guide Program on Breast Cancer Awareness DayOctober 23, 2023 | finance.yahoo.comZhongchao Inc. Introduces PRO-Based Disease Management Model for Lung Cancer PatientsSeptember 25, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCBSC, PASG, ABVC, and ZCMD Company DescriptionsABVC BioPharma NASDAQ:ABVC$1.77 -0.08 (-4.32%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.80 +0.03 (+1.75%) As of 06/13/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.CB Scientific OTCMKTS:CBSC$0.04 0.00 (0.00%) As of 06/13/2025CB Scientific, Inc., through its US and international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians.Passage Bio NASDAQ:PASG$0.39 -0.04 (-9.07%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.40 +0.00 (+1.02%) As of 06/13/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Zhongchao NASDAQ:ZCMD$1.15 -0.17 (-12.88%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.32 +0.18 (+15.22%) As of 06/13/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zhongchao Inc. provides healthcare information, education, and training services in the People's Republic of China. The company offers online and onsite health information services, healthcare education programs, and healthcare training products, including clinical practice training, open classes of popular medical topics, interactive case studies, academic conference and workshops, continuing education courses, and articles and short videos with educational healthcare content. It also provides customized medical courses and medical training services; and patient management services through online platform under the Zhongxun brand. The company operates through its mdmooc.org online platform under the MDMOOC brand; and Sunshine Health Forums, a Wechat subscription account and mobile app. It serves enterprises, non-for-profit organizations, and medical journals, as well as healthcare professionals, nurses, doctors, and other healthcare workers. The company was founded in 2012 and is headquartered in Shanghai, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
